40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods

4DMedical caught bids this week and finished on top.

| More on:
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Investors are bidding up the 4DMedical share price hard this week after a key announcement
  • The launch of the company's XV Scanner is a key driver to the commercialisation of its XV Technology strategy, it says
  • In the last 12 months, the 4DMedical share price has sunk by 44%

The 4DMedical Ltd (ASX: 4DX) share price climbed higher on Friday afternoon to close up 1.18% at 85.5 cents.

Investors appear to be rallying behind Thursday's announcement, which revealed the company is launching the world's first dedicated lung scanner.

The 4DMedical share price soared almost 20% yesterday. It's likely that momentum spilled over into today's session as trading volume surged well past its four-week average at 764,665 shares.

With big gains also on Tuesday and Wednesday, it means 4DMedical shares have surged 41% since last Friday's close. This week's gain is a welcome reprieve for 4D shareholders, who've seen their holdings evaporate over the past 12 months.

TradingView Chart

What's been happening at 4DMedical?

The company advised that it has installed the 'XV Scanner' at the Prince of Wales Hospital in Sydney after it was unveiled to the Federal health minister on Thursday.

4D says the scanner will provide unparalleled access to visually map the lung and provides "highly visual insight into lung function".

A successful launch will hopefully see the market adopt its XV Technology, something the company says is integral to successful commercialisation.

But the benefits extend primarily to the doctor-patient realm, and the scanner itself is considered somewhat a "breakthrough in innovation", according to Lung Foundation Australia CEO, Mark Brooke.

It's reported that seven million Australian currently are living with or are impacted by lung disease in some way, therefore any breakthrough would be a welcome sigh of relief to many.

Evans and Partners have 4DMedical rated as a speculative buy and value the company at $1.50 per share, suggesting an upside potential of 75% at the time of writing.

Meanwhile, Bell Potter has the company rated as a speculative hold but sets a price target of $2.07 per share — a mammoth 142% upside potential.

According to Bloomberg data, the consensus valuation is $1.78 per share, still a considerable amount of upside potential if the bull case plays out to that level.

4DMedical share price snapshot

In the last 12 months, the 4DMedical share price has sunk and is now 44% in the red. It is also down 36% this year to date.

Despite the 40% gain this week, shares have still fallen into the red by 5% over the past month.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A red heart-shaped balloon floats up above the plain white ones, indicating the best shares.
Healthcare Shares

Heart tech firm's shares surge after huge capital raise

A strategic investor has also jumped on board.

Read more »

Lab technician in lab with a tray of specimens
Healthcare Shares

Has this ASX 200 stock just turned the corner after 7% surge?

Brokers think the volatile biotech share can sustain the rally this time.

Read more »

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 ASX shares tipped to climb over 100% in 2026

Analysts expect steep gains this year.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »